ClinicalTrials.gg
CompletedNCT05516342Updated Dec 2, 2024Results posted

LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers

An interventional study of LEAD IT! Programming in Dementia, Vascular, Alzheimer Disease and Dementia, Mixed, sponsored by Hopeful Aging. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Hopeful Aging · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Dementia, Vascular with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Dementia, Vascular · United States.

Enrollment
19th of 47
182 · median 100
Started
2020
with 5 others
No phase
33 of 65
7 open now
Registered
44th of 65
by date
Lead sponsor
6 of 65
Hopeful Aging

Among the 65 studies in Dementia, Vascular with a site in United States, this one is the 19th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 with no phase, and was the 44th registered.

Dementia, Vascular

183 studies on the registry are indexed under Dementia, Vascular; 42 are open to participants now.

Browse Dementia, Vascular studies →

Open to participants now

16 of the 65 studies in Dementia, Vascular with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dementia, Vascular studies recruiting now, 25 (71%) set no upper age limit and 2 (6%) stop at 75 or younger; 4 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dementia, Vascular with a site in United States, or all of them as a file.
02

Study summary

The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with dementia). The study will examine the clinical outcomes of long-term use of the app by both Resident Leaders (RLs) and Resident Players (RPs).

The Specific Aims of the proposed Phase 2 project are to:

  1. Develop improved Beta 1 and Beta 2 Versions of LEAD IT! with sufficient content to facilitate six activities twice per week for 4.5 months.
  2. Examine the extent to which RLs are able to serve as leaders while using LEAD IT!
  3. Examine the effects of resident-led LEAD IT! programming on RPs.
  4. Examine PWD and staff satisfaction with LEAD IT!
Read the detailed description

he proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, as well as examine the clinical outcomes of long-term use of the app by both RLs and RPs.

The Specific Aims of the proposed Phase 2 project are to:

  1. Develop improved Beta 1 and Beta 2 Versions of LEAD IT! with sufficient content to facilitate six activities twice per week for 4.5 months. During Months 1-7, the Beta 1 version of the app will be created by the study's Development Team (DT). During Months 13-15, the DT will create an improved Beta 2 version, based on lessons learned in Beta 1 testing.
  2. Examine the extent to which RLs are able to serve as leaders while using LEAD IT! During all intervention sessions, researchers will track the extent to which each RL follows key steps involved in leading each activity. RLs will be considered successful if they follow the steps 80% of the time and require less staff assistance on less than 20% of steps.
  3. Examine the effects of resident-led LEAD IT! programming on RPs. Two quasi-experiments will be conducted. Experiment #1, which will test the Beta 1 version of LEAD IT!, will use a pre-post design. Proximal (immediate) effects will be assessed by examining RP's levels of engagement/affect during baseline (standard) activities and again during LEAD IT! activities. It is hypothesized that LEAD IT! will result in higher quality engagement than baseline activities. Experiment #2, which will test the Beta 2 version of the app, will be a cluster randomized trial (CRT), consisting of pre- and post-intervention measurements of a Treatment Group (TG)-which will consist of PWD who receive the intervention - and a Control Group (CG) - which will consist of PWD who receive standard programming / care. Since Experiment #2 will occur after all improvements to the app have been made, it will represent the definitive trial of the LEAD IT! app's impact on PWD. For proximal (immediate) measures, it is anticipated that there will be a Group x Time interaction effect, with TG participants exhibiting significantly greater increases in positive forms of engagement, as compared to CG participants. For distal measures, it is anticipated that there will be a Group x Time interaction effect, with TG participants exhibiting significantly greater increases in quality of life (based upon the DEMQOL) at treatment, as compared to CG participants.
  4. Examine PWD and staff satisfaction with LEAD IT! This will be achieved by eliciting feedback from PWD and staff members. PWD and staff members will be considered "highly satisfied" with the app if 85% are satisfied with the app.
03

Conditions studied

  • Dementia, Vascular
  • Alzheimer Disease
  • Dementia, Mixed

Keywords

  • psychosocial
  • social
  • non-pharmacological intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Persons with Dementia

  • Must reside in an Assisted Living Facility or NH
  • Must be at least 65 years old
  • Must speak and read English
  • Must have a clinical diagnosis of dementia (any type).
  • Resident-players must score at least five on the (MMSE)
  • Resident-leaders must score at least 13 on the MMSE
  • Resident-leaders must possess at least 70% of the characteristics of successful leaders, based upon the I'm Still Here Skills Inventory, Short Edition, Modified

Exclusion Criteria for Persons with Dementia -the person shows signs of rapid cognitive decline or physical deterioration over the last six months, as evidenced by medical records.

Inclusion Criteria for Staff

  • Must be at least 18 years old
  • Must speak English

Exclusion Criteria for Staff

-n/a

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Experimental: Experimental, LEAD IT! Programming

    Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.

    Behavioral: LEAD IT! Programming

  • No intervention
    No Intervention: Control, Standard Care / Programming

    Participants in the Control arm will receive standard care / programming.

Interventions

  • BehavioralLEAD IT! Programming

    LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale [Time Frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

    Constructive Engagement on the Menorah Park Engagement Scale is defined as doing or commenting on something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome.

    Time frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

  2. Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale

    Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity.During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome..

    Time frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

  3. Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale

    Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

  4. Change From Baseline to Treatment for Non Engagement on the Menorah Park Engagement Scale

    Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Non-Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

  5. Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale

    Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Pleasure is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

Secondary outcomes

  1. Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

    The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

    Time frame: Baseline (Month 1) and Post-Treatment (Month 4)

  2. Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

    The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symptoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

    Time frame: Baseline (Month 1) and Post-Treatment (Month 4)

  3. Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

    The GDS-SF consists of 15 questions requiring "yes" or "no" answers. It is specifically developed for use with older adults. For persons unable to answer the questions, a proxy can be used. The total score ranges from 0 to 15, with lower scores indicating a better outcome.

    Time frame: Baseline (Month 1) and Post-Treatment (Month 4)

  4. Change From Baseline to Treatment on the Cohen Mansfield Agitation Inventory (CMAI)

    The 14-item CMAI is a caregiver rated questionnaire using a 5-point Likert scale to rate the frequency of disturbing behaviors in dementia such as verbal/physical aggression, general restlessness, strange noises, and so on. Scores range from 14 to 70, with lower scores indicating a better outcome.

    Time frame: Baseline (Month 1) and Post-Treatment (Month 4)

07

Results

Posted Dec 2, 2024

Participant flow

Baseline
Participant flow — Baseline
MilestonePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Started5441
Completed5441
Not completed00
Treatment
Participant flow — Treatment
MilestonePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Started5441
Completed5137
Not completed34
Post Treatment
Participant flow — Post Treatment
MilestonePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Started5137
Completed4735
Not completed42

Outcome measures

PrimaryChange From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale [Time Frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)

Constructive Engagement on the Menorah Park Engagement Scale is defined as doing or commenting on something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome.

Time frame:
Baseline (Month 1) and Treatment (Months 2, 3, and 4)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale [Time Frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)
score on a scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale [Time Frame: Baseline (Month 1) and Treatment (Months 2, 3, and 4)0.19 ± 0.53-0.24 ± 0.50
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = <0.01
PrimaryChange From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale

Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity.During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome..

Time frame:
Baseline (Month 1) and Treatment (Months 2, 3, and 4)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale
score on a scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale0.69 ± 0.65-0.12 ± 0.55
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = <0.01
PrimaryChange From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale

Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Month 1) and Treatment (Months 2, 3, and 4)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale
score on a scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale-0.32 ± 0.480.28 ± 0.50
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = <0.01
PrimaryChange From Baseline to Treatment for Non Engagement on the Menorah Park Engagement Scale

Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Non-Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Month 1) and Treatment (Months 2, 3, and 4)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Non Engagement on the Menorah Park Engagement Scale
score on a scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment for Non Engagement on the Menorah Park Engagement Scale-.24 ± 0.350.02 ± 0.41
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = <0.01
PrimaryChange From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale

Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling. During baseline, multiple observations of "standard" activities were observed and a single mean score was calculated for all sessions observed during that month. Then, again, during treatment, multiple treatment activity sessions were observed over the course of three months (Months 2, 3, and 4) and a single mean score was calculated. The minimum value for Pleasure is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Month 1) and Treatment (Months 2, 3, and 4)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale
score on a scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale0.32 ± 0.25-0.02 ± 0.27
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = <0.01
SecondaryChange From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

Time frame:
Baseline (Month 1) and Post-Treatment (Month 4)
Reported as:
Mean · score on scale
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)
score on scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)1.51 ± 11.751.08 ± 15.39
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = 0.89
SecondaryChange From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symptoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

Time frame:
Baseline (Month 1) and Post-Treatment (Month 4)
Reported as:
Mean · score on scale
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)
score on scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)-0.15 ± 15.323.06 ± 9.04
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = 0.27
SecondaryChange From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

The GDS-SF consists of 15 questions requiring "yes" or "no" answers. It is specifically developed for use with older adults. For persons unable to answer the questions, a proxy can be used. The total score ranges from 0 to 15, with lower scores indicating a better outcome.

Time frame:
Baseline (Month 1) and Post-Treatment (Month 4)
Reported as:
Mean · score on scale
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)
score on scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)-0.71 ± 2.730.38 ± 4.58
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = 0.19
SecondaryChange From Baseline to Treatment on the Cohen Mansfield Agitation Inventory (CMAI)

The 14-item CMAI is a caregiver rated questionnaire using a 5-point Likert scale to rate the frequency of disturbing behaviors in dementia such as verbal/physical aggression, general restlessness, strange noises, and so on. Scores range from 14 to 70, with lower scores indicating a better outcome.

Time frame:
Baseline (Month 1) and Post-Treatment (Month 4)
Reported as:
Mean · score on scale
Change From Baseline to Treatment on the Cohen Mansfield Agitation Inventory (CMAI)
score on scalePersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
Change From Baseline to Treatment on the Cohen Mansfield Agitation Inventory (CMAI)-0.21 ± 4.532.00 ± 7.57
Statistical analysis
  • Persons With Dementia, Experimental (LEAD IT! Programming) vs Persons With Dementia, Control (Standard Care / Activity Programming) · ANOVA · p = 0.10

Adverse events

Collected over 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Persons With Dementia, Experimental (LEAD IT! Programming)2/54 (3.7%)4/54 (7.4%)0/54 (0%)
Persons With Dementia, Control (Standard Care / Activity Programming)4/41 (9.8%)7/41 (17.1%)0/41 (0%)
Most frequent serious events
Most frequent serious events
EventPersons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)
DeathInjury, poisoning and procedural complications2/544/41
Acute Illness or Injury, Sent to hospitalInjury, poisoning and procedural complications2/543/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
<=18 years000
Between 18 and 65 years000
>=65 years544195
Age, Continuous
Age, Continuous(years)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
Mean87.13 ± 7.3986.54 ± 7.0686.87 ± 7.21
Sex: Female, Male
Sex: Female, Male(Participants)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
Female472673
Male71522
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
Hispanic or Latino000
Not Hispanic or Latino544195
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American718
White464086
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Persons With Dementia, Experimental (LEAD IT! Programming)Persons With Dementia, Control (Standard Care / Activity Programming)Total
United States544195
08

Study locations

1 site
  • The Hearthstone Institute, LLC
    Winchester, Massachusetts 01890, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2023, 31 months.

Results were first posted in Dec 2024, 1 year 5 months after primary completion.

Of 53 interventional studies with no phase under Dementia, Vascular, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 53. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 25, 2022
StartActual
Nov 10, 2020
Primary completionActual
Jun 11, 2023
CompletionActual
Jun 11, 2023
Results first posted
Dec 2, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05516342
Lead sponsor
Hopeful Aging
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Nov 10, 2020
Primary completion
Jun 11, 2023
Completion
Jun 11, 2023
Results posted
Dec 2, 2024
Last update
Dec 2, 2024

Study contacts

Michael Skrajner, MA
principal investigator · Hearthstone

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion